Teva Pharmaceutical Industries has introduced an authorized generic of ACTOplus met (pioglitazone/metformin tablets) 15mg/500mg, 15mg/850mg. ACTOplus met is marketed by Takeda Pharmaceuticals USA and used with diet and exercise to improve ...
Tags: Teva Pharmaceutical Industries, pioglitazone tablets, metformin tablets
US packaging technology firm MOCON has struck a deal to acquire Denmark-based specialized instrumentation maker Dansensor for $20m. The agreement which involves certain customary conditions, is expected to be closed by 2 April 2012. The ...
RayBiotech-developed antibody-based biomarker screening assays have been used to identify a critical pathway involved in chemotherapeutic resistance acquired by melanoma cancer cells. RayBiotech president and chief operating officer ...
Tags: medical research, clinical technology, RayBiotech's antibody arrays
Evotec and Haplogen have signed a drug discovery partnership targeting viral infectious diseases. The drugs resulting from the partnership are expected to target a human protein that is vital for the spread of pathogenic viral ...
Tags: the human protein, targeting viral infectious diseases, Haplogen, Evotec
Full Spectrum Genetics and BioBlocks have signed an agreement to find new Small Molecule Therapeutics for protein-protein interactions As part of the agreement, Full Spectrum Genetics protein analysis and engineering platform, MapEng, and ...
Tags: Full Spectrum Genetics, BioBlocks, new small molecule therapeutics
BioFocus, the Galapagos' service division, and Ono Pharmaceutical have signed a new drug discovery agreement focusing on CNS disorders. BioFocus managing director and Galapagos Services SVP Dr. Chris Newton said, "This project plays to ...
TNI BioTech and Hubei Qianjiang Pharmaceutical have entered into a partnership to develop new cancer therapeutics. The cancer drugs will be based on TNI BioTech's patents covering Methionine Enkephalin. TNI BioTech will carry out ...
Tags: Hubei Qianjiang Pharmaceutical, cancer drugs, methionine enkephalin
PharmaInformatic has developed a comprehensive database on bioavailability to develop targeted new drugs. The new knowledge base, called PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) combines the results ...
Gourd is the fruit of a kind of liana.When fresh and tender,it could be eaten as vegetable;when dried,it makes an ideal container of water or wine.Northern Chinese farmers have the habit of cutting a gourd in two to be used wine containers ...
Galenea and collaborator Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School have won a five year $3m grant from the National Institute of Mental Health (NIMH). The grant is intended for the development of ...
The 5th International Conference on Clinical Trials for Alzheimer's Disease (CTAD) will examine the phase 3 treatment trials of Alzheimer's Disease (AD) and also analyze the results to develop current and new drugs to tackle AD. The ...
Tags: CTAD, AD, Alzheimer's Disease
German-based Evotec has partnered with Probiodrug to advance the development operations of drugs targeting major age related diseases such as Alzheimer's disease(AD). Evotec will support the pre-clinical and clinical development of ...
Tags: Alzheimer's disease, Evotec, glutaminyl cyclase, neurodegeneration
Sweden based Karolinska Institutet and Immunomedics scientists have collaborated to design and test new class of drugs that destroy the AIDS virus, HIV (Human Immunodeficiency Virus), which may also help in eliminating the virus completely. ...
Tags: Immunomedics, anti-HIV agents, virus
The Anti-Infective Drugs Advisory Committee (AIDAC) to the US Food and Drug Administration (FDA) has recommended the use of Novartis's tobramycin inhalation powder (TIP) to treat cystic fibrosis (CF) patients whose lungs contain bacteria ...
Prosetta Antiviral has entered into a multi-year collaboration with Bristol-Myers Squibb Company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. The collaboration will focus on ...